Molecular/biomarker testing in lung cytology: A practical approach. Issue 1 (13th September 2022)

• Record Type: Journal Article
• Authors: Schmitt, Fernando; Lozano, Maria D.
• Other Names: Schmitt Fernando guestEditor.; Yang Zhongbo guestEditor.; Esebua Magda guestEditor.
• Is Part Of: Diagnostic cytopathology. Volume 51:Issue 1(2023)
• Page Start: 59
• Page End: 67
• Publication Date: 2022-09-13
• Subjects: biomarkers -- cytopathology -- molecular testing -- non‐small cell lung carcinoma; Cytodiagnosis -- Periodicals; Pathology, Cellular -- Periodicals; Cytology -- Periodicals; 616.07582
• DOI: 10.1002/dc.25054
• Languages: English
• ISSNs: 8755-1039

Abstract

Abstract: The increasing comprehension of molecular mechanisms underlying lung cancer and the discovery of targetable genomic alterations has dramatically change the pathological approach to lung cancer, especially non‐small cell lung cancer (NSCLC). This unstoppable knowledge has taken pathologists to the leading front on lung cancer management. This is especially relevant in the world of cytopathology where "doing more with less" is a daily challenge. Nowadays with a growing number of predictive biomarkers needed to manage patients with NSCLC, there has been a paradigm shift in care and handling of diagnostic samples. One of the main emphasis and interest relies on the utilization of cytologic samples and small biopsies for not only diagnostic purposes but also for ancillary testing. Moreover, lung cytopathology is in continuous evolutions with implementation of new diagnostic techniques, new tools, and facing new challenges. The goal of this paper will be to provide the reader with the necessary concepts than can be used to exploit the cytological samples in order to use these samples for comprehensive diagnosis and relevant ancillary testing purposes.